Topics:

ALK-1 receptor: New target in angiogenesis

ALK-1 receptor: New target in angiogenesis

Pfizer Oncology is working with a fully human, IgG2 monoclonal antibody (PF-03446962) that is directed against an activin-like receptor kinase 1 (ALK-1) target. An early investigation indicates that neutralizing ALK-1 with PF-03446962 can disturb tumor endothelial cell function and impair tumor angiogenesis, according to the company (AACR 2009 abstract 2007).

 
Loading comments...
Please Wait 20 seconds or click here to close